Recruiting
Breast cancer metastatic+2
RecruitingStudy on the Safety and Effects of Vosilasarm Alone and in Combination for Patients with Relapsed Advanced or Metastatic Breast Cancer
Registered drugNo placebo
Study on the Safety and Effects of Vosilasarm Alone and in Combination for Patients with Relapsed Advanced or Metastatic Breast Cancer
Registered drugNo placebo
- Disease:Breast cancer metastaticHormone receptor positive HER2 negative breast cancer+1
- Substances:ElacestrantVosilasarm
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Elacestrant
- Sponsor:Ellipses Pharma Limited